{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Health+Tag&page=6",
    "query": {
      "intervention": "Health Tag",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 535,
    "total_pages": 54,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Health+Tag&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Health+Tag&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T03:25:54.752Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03723616",
      "title": "Reactions to Warnings on Hookah Ads",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Reactions to Warnings",
        "Hookah Smoking"
      ],
      "interventions": [
        {
          "name": "Ads Only",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Ads with text-only health warning labels (HWLs)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Ads with text + graphic health warning labels (HWLs)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "34 Years",
        "sex": "ALL",
        "summary": "18 Years to 34 Years"
      },
      "enrollment_count": 2588,
      "start_date": "2018-10-05",
      "completion_date": "2021-03-26",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03723616"
    },
    {
      "nct_id": "NCT03216499",
      "title": "HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "HIF-2alpha Inhibitor PT2385",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-09-14",
      "completion_date": "2020-06-05",
      "has_results": true,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03216499"
    },
    {
      "nct_id": "NCT02889133",
      "title": "Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Iron Deficiency"
      ],
      "interventions": [
        {
          "name": "Iron-dextran",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Blood Donation",
          "type": "PROCEDURE"
        },
        {
          "name": "24-hour PTR",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 79,
      "start_date": "2017-01",
      "completion_date": "2021-10-05",
      "has_results": true,
      "last_update_posted_date": "2024-06-12",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02889133"
    },
    {
      "nct_id": "NCT06907290",
      "title": "A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis D Infection"
      ],
      "interventions": [
        {
          "name": "Brelovitug 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Brelovitug 900 mg",
          "type": "DRUG"
        },
        {
          "name": "Delayed Treatment with Brelovitug 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-03-25",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 10,
      "location_summary": "Long Beach, California • Los Angeles, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cities in Iowa",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06907290"
    },
    {
      "nct_id": "NCT02138825",
      "title": "Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary"
      ],
      "interventions": [
        {
          "name": "Riociguat (Adempas, BAY63-2521)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 147,
      "start_date": "2014-06-04",
      "completion_date": "2016-09-14",
      "has_results": true,
      "last_update_posted_date": "2017-12-04",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138825"
    },
    {
      "nct_id": "NCT04014790",
      "title": "RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Vs Host Disease",
        "Graft-versus-host-disease",
        "Acute-graft-versus-host Disease",
        "Prevention of aGVHD"
      ],
      "interventions": [
        {
          "name": "RGI-2001",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regimmune Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 49,
      "start_date": "2019-11-25",
      "completion_date": "2023-04-03",
      "has_results": true,
      "last_update_posted_date": "2024-05-28",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Miami, Florida • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04014790"
    },
    {
      "nct_id": "NCT06296355",
      "title": "Impacts of Warning Labels on Ultra-Processed Foods",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Health Behavior",
        "Diet, Healthy"
      ],
      "interventions": [
        {
          "name": "Health Warning Label",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Identity Warning Label",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Barcode Label",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 4000,
      "start_date": "2024-08-09",
      "completion_date": "2024-09-11",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06296355"
    },
    {
      "nct_id": "NCT02225574",
      "title": "An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "MEK-162",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib",
          "type": "DRUG"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-03-11",
      "completion_date": "2017-02-02",
      "has_results": false,
      "last_update_posted_date": "2020-02-12",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02225574"
    },
    {
      "nct_id": "NCT03170232",
      "title": "A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Danirixin 35 mg tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metered dose inhaler (MDI) sensor device",
          "type": "DEVICE"
        },
        {
          "name": "Rescue medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "40 Years to 76 Years"
      },
      "enrollment_count": 54,
      "start_date": "2017-10-16",
      "completion_date": "2018-11-15",
      "has_results": true,
      "last_update_posted_date": "2020-07-31",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Diego, California • Torrance, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170232"
    },
    {
      "nct_id": "NCT05317663",
      "title": "Developing and Testing Waterpipe-specific Health Warning Labels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Waterpipe Smoking",
        "Health Warning Label",
        "Harm Perception",
        "Puffing Behaviour",
        "Quitting Smoking",
        "Health Risk Behaviors"
      ],
      "interventions": [
        {
          "name": "Test Health Warning Label (HWL)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Test without Health Warning Label (no-HWL)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Florida International University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "21 Years to 35 Years"
      },
      "enrollment_count": 44,
      "start_date": "2022-10-03",
      "completion_date": "2024-12-09",
      "has_results": false,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-11-01T03:25:54.752Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05317663"
    }
  ]
}